A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not ...

Eli Lilly (LLY) on Saturday reported positive results from two late-stage clinical trials of its experimental obesity drug ...

Eli Lilly and Company announced additional positive results today from pivotal Phase 3 trials of its investigational weight loss drug, retatrutide. The data, presented at the American Diabetes ...

Wegovy is the first GLP-1 approved for weight loss, but there are several new GLP-1 drugs in development. One of the most anticipated new weight-loss drugs also helped people struggling with common ...

Eli Lilly's latest trial results show that its advanced obesity medication, Retatrutide, not only aids in weight reduction ...

Studies in mice reveal a new target for potentially treating and preventing life-threatening cardiovascular complications in ...

For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss. It may be fewer ...

Doctors are divided on testosterone and warn many patients may not need it. Here’s how to know if you actually should be on ...

Eli Lilly just released impressive study results for retatrutide, an investigational weight loss drug that targets three ...

The nightly pill could offer a game-changing alternative form of treatment, new results of a large clinical trial show. AD109 ...

Explore conditions GLP-1s may treat beyond weight loss, including FDA-approved uses for sleep apnea, cardiovascular and kidney disease.